ES2753779T3 - Blautia stercosis y wexlerae para la utilización en el tratamiento de enfermedades inflamatorias y autoinmunes - Google Patents
Blautia stercosis y wexlerae para la utilización en el tratamiento de enfermedades inflamatorias y autoinmunes Download PDFInfo
- Publication number
- ES2753779T3 ES2753779T3 ES16731640T ES16731640T ES2753779T3 ES 2753779 T3 ES2753779 T3 ES 2753779T3 ES 16731640 T ES16731640 T ES 16731640T ES 16731640 T ES16731640 T ES 16731640T ES 2753779 T3 ES2753779 T3 ES 2753779T3
- Authority
- ES
- Spain
- Prior art keywords
- composition
- asthma
- disease
- blautia
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 117
- 230000002757 inflammatory effect Effects 0.000 title claims abstract description 50
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 24
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 23
- 241001202853 Blautia Species 0.000 title claims description 45
- 239000000203 mixture Substances 0.000 claims abstract description 240
- 230000001580 bacterial effect Effects 0.000 claims abstract description 140
- 238000000034 method Methods 0.000 claims abstract description 57
- 230000002265 prevention Effects 0.000 claims abstract description 40
- 241001038648 Blautia wexlerae Species 0.000 claims abstract description 31
- 241000335560 Blautia stercoris Species 0.000 claims abstract description 25
- 208000006673 asthma Diseases 0.000 claims description 157
- 102000013691 Interleukin-17 Human genes 0.000 claims description 93
- 108050003558 Interleukin-17 Proteins 0.000 claims description 93
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 84
- 201000010099 disease Diseases 0.000 claims description 79
- 210000004027 cell Anatomy 0.000 claims description 63
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 56
- 206010046851 Uveitis Diseases 0.000 claims description 47
- 201000006417 multiple sclerosis Diseases 0.000 claims description 39
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 28
- 210000000068 Th17 cell Anatomy 0.000 claims description 23
- 206010003246 arthritis Diseases 0.000 claims description 20
- 201000009961 allergic asthma Diseases 0.000 claims description 14
- 238000002560 therapeutic procedure Methods 0.000 claims description 14
- 235000013305 food Nutrition 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 13
- 208000008795 neuromyelitis optica Diseases 0.000 claims description 10
- 206010029379 Neutrophilia Diseases 0.000 claims description 9
- 230000024245 cell differentiation Effects 0.000 claims description 8
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 7
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 6
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 6
- 201000005671 spondyloarthropathy Diseases 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 208000009137 Behcet syndrome Diseases 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 208000015943 Coeliac disease Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 5
- 206010014561 Emphysema Diseases 0.000 claims description 5
- 206010023232 Joint swelling Diseases 0.000 claims description 5
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 5
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 5
- 206010057430 Retinal injury Diseases 0.000 claims description 5
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 5
- 206010047115 Vasculitis Diseases 0.000 claims description 5
- 201000010105 allergic rhinitis Diseases 0.000 claims description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims description 5
- 230000024949 interleukin-17 production Effects 0.000 claims description 5
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- 201000001245 periodontitis Diseases 0.000 claims description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 206010014950 Eosinophilia Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 206010039705 Scleritis Diseases 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 238000010172 mouse model Methods 0.000 description 93
- 241001465754 Metazoa Species 0.000 description 77
- 239000003981 vehicle Substances 0.000 description 68
- 238000004458 analytical method Methods 0.000 description 49
- 210000001519 tissue Anatomy 0.000 description 48
- 241000699670 Mus sp. Species 0.000 description 45
- 230000009467 reduction Effects 0.000 description 43
- 102000004127 Cytokines Human genes 0.000 description 42
- 108090000695 Cytokines Proteins 0.000 description 42
- 210000004072 lung Anatomy 0.000 description 41
- 230000001404 mediated effect Effects 0.000 description 38
- 230000028709 inflammatory response Effects 0.000 description 36
- 206010061218 Inflammation Diseases 0.000 description 35
- 230000004054 inflammatory process Effects 0.000 description 35
- 239000000428 dust Substances 0.000 description 33
- 241000894006 Bacteria Species 0.000 description 32
- 241000238711 Pyroglyphidae Species 0.000 description 27
- 229940046533 house dust mites Drugs 0.000 description 27
- 210000000440 neutrophil Anatomy 0.000 description 26
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 23
- 230000037361 pathway Effects 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- 230000006378 damage Effects 0.000 description 21
- 230000008595 infiltration Effects 0.000 description 20
- 238000001764 infiltration Methods 0.000 description 20
- 230000002829 reductive effect Effects 0.000 description 20
- 210000000988 bone and bone Anatomy 0.000 description 18
- 239000013641 positive control Substances 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 17
- 230000037396 body weight Effects 0.000 description 16
- 210000003979 eosinophil Anatomy 0.000 description 15
- 239000008194 pharmaceutical composition Substances 0.000 description 15
- 230000004044 response Effects 0.000 description 14
- 210000000936 intestine Anatomy 0.000 description 13
- 108090001005 Interleukin-6 Proteins 0.000 description 12
- 239000002158 endotoxin Substances 0.000 description 12
- 239000002054 inoculum Substances 0.000 description 12
- 229920006008 lipopolysaccharide Polymers 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- 230000018109 developmental process Effects 0.000 description 11
- 230000002327 eosinophilic effect Effects 0.000 description 11
- 239000012530 fluid Substances 0.000 description 11
- 230000036961 partial effect Effects 0.000 description 11
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 10
- 102100040247 Tumor necrosis factor Human genes 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 210000000845 cartilage Anatomy 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000009696 proliferative response Effects 0.000 description 10
- 230000002207 retinal effect Effects 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000012228 culture supernatant Substances 0.000 description 9
- 210000001503 joint Anatomy 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 9
- 230000035800 maturation Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 239000013642 negative control Substances 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 210000004988 splenocyte Anatomy 0.000 description 9
- 208000017667 Chronic Disease Diseases 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 8
- 102000000503 Collagen Type II Human genes 0.000 description 8
- 108010041390 Collagen Type II Proteins 0.000 description 8
- 208000009386 Experimental Arthritis Diseases 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 102000003814 Interleukin-10 Human genes 0.000 description 8
- 108090000174 Interleukin-10 Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 108700012920 TNF Proteins 0.000 description 8
- 230000002159 abnormal effect Effects 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 108090000978 Interleukin-4 Proteins 0.000 description 7
- 102000004388 Interleukin-4 Human genes 0.000 description 7
- 206010033799 Paralysis Diseases 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 229960003957 dexamethasone Drugs 0.000 description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 7
- 244000005709 gut microbiome Species 0.000 description 7
- 238000003384 imaging method Methods 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 235000013336 milk Nutrition 0.000 description 7
- 239000008267 milk Substances 0.000 description 7
- 210000004080 milk Anatomy 0.000 description 7
- 238000001543 one-way ANOVA Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 206010007710 Cartilage injury Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- -1 IL17-F Proteins 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 235000013406 prebiotics Nutrition 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 230000007115 recruitment Effects 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 206010020718 hyperplasia Diseases 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 238000007492 two-way ANOVA Methods 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 206010051728 Bone erosion Diseases 0.000 description 4
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 108010058846 Ovalbumin Proteins 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 description 4
- 239000005862 Whey Substances 0.000 description 4
- 102000007544 Whey Proteins Human genes 0.000 description 4
- 108010046377 Whey Proteins Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000001188 articular cartilage Anatomy 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 231100000518 lethal Toxicity 0.000 description 4
- 230000001665 lethal effect Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 229940062713 mite extract Drugs 0.000 description 4
- 230000007659 motor function Effects 0.000 description 4
- 230000008392 neutrophilic inflammatory response Effects 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 238000003305 oral gavage Methods 0.000 description 4
- 229940092253 ovalbumin Drugs 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 230000000529 probiotic effect Effects 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 4
- 239000004299 sodium benzoate Substances 0.000 description 4
- 235000010234 sodium benzoate Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 210000001364 upper extremity Anatomy 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 239000007169 ycfa-medium Substances 0.000 description 4
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000002691 Choroiditis Diseases 0.000 description 3
- 229930105110 Cyclosporin A Natural products 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 108010002335 Interleukin-9 Proteins 0.000 description 3
- 102000000585 Interleukin-9 Human genes 0.000 description 3
- 238000012313 Kruskal-Wallis test Methods 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001111421 Pannus Species 0.000 description 3
- 108010081690 Pertussis Toxin Proteins 0.000 description 3
- 206010035039 Piloerection Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 208000003971 Posterior uveitis Diseases 0.000 description 3
- 208000025749 Vogt-Koyanagi-Harada disease Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 229940126587 biotherapeutics Drugs 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000001612 chondrocyte Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 230000009266 disease activity Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 201000002491 encephalomyelitis Diseases 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 230000005713 exacerbation Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 238000012543 microbiological analysis Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 230000005371 pilomotor reflex Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 102000029752 retinol binding Human genes 0.000 description 3
- 108091000053 retinol binding Proteins 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 2
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 2
- 102100035793 CD83 antigen Human genes 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 2
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 2
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 102100033105 Interleukin-17C Human genes 0.000 description 2
- 108010082786 Interleukin-1alpha Proteins 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 102100039897 Interleukin-5 Human genes 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 description 2
- 241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 101000872823 Xenopus laevis Probable histone deacetylase 1-A Proteins 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 208000028752 abnormal posture Diseases 0.000 description 2
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 2
- 229960004977 anhydrous lactose Drugs 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 238000013475 authorization Methods 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 201000004982 autoimmune uveitis Diseases 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000001815 biotherapy Methods 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 108010079058 casein hydrolysate Proteins 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000001609 comparable effect Effects 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 230000000093 cytochemical effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000005786 degenerative changes Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000008102 immune modulation Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 108010074108 interleukin-21 Proteins 0.000 description 2
- 108010074109 interleukin-22 Proteins 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 208000018937 joint inflammation Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000003843 mucus production Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000003448 neutrophilic effect Effects 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004256 retinal image Effects 0.000 description 2
- 238000010845 search algorithm Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000021262 sour milk Nutrition 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 235000008939 whole milk Nutrition 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- 229930195724 β-lactose Natural products 0.000 description 2
- RWIUTHWKQHRQNP-ZDVGBALWSA-N (9e,12e)-n-(1-phenylethyl)octadeca-9,12-dienamide Chemical compound CCCCC\C=C\C\C=C\CCCCCCCC(=O)NC(C)C1=CC=CC=C1 RWIUTHWKQHRQNP-ZDVGBALWSA-N 0.000 description 1
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 235000007558 Avena sp Nutrition 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241001464894 Blautia producta Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 102000006303 Chaperonin 60 Human genes 0.000 description 1
- 108010058432 Chaperonin 60 Proteins 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000338671 Coenonympha caeca Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000014526 Conduction disease Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 1
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 1
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 1
- 101000853000 Homo sapiens Interleukin-26 Proteins 0.000 description 1
- 101000904196 Homo sapiens Pancreatic secretory granule membrane major glycoprotein GP2 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 102000039989 IL-17 family Human genes 0.000 description 1
- 108091069193 IL-17 family Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102100033461 Interleukin-17A Human genes 0.000 description 1
- 102100033096 Interleukin-17D Human genes 0.000 description 1
- 102100036672 Interleukin-23 receptor Human genes 0.000 description 1
- 102100036679 Interleukin-26 Human genes 0.000 description 1
- 108010066979 Interleukin-27 Proteins 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 206010061599 Lower limb fracture Diseases 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 229910017621 MgSO4-7H2O Inorganic materials 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 102100024019 Pancreatic secretory granule membrane major glycoprotein GP2 Human genes 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- 108020001027 Ribosomal DNA Proteins 0.000 description 1
- CZMRCDWAGMRECN-UHFFFAOYSA-N Rohrzucker Natural products OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
- 241000192031 Ruminococcus Species 0.000 description 1
- 101150099493 STAT3 gene Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241001185310 Symbiotes <prokaryote> Species 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 229960004784 allergens Drugs 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000015155 buttermilk Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006041 cell recruitment Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 235000020186 condensed milk Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 235000019543 dairy drink Nutrition 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000001210 effect on neutrophils Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 235000019541 flavored milk drink Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 102000054350 human CHI3L1 Human genes 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 108040001844 interleukin-23 receptor activity proteins Proteins 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000001964 microbiological growth medium Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000007407 panuveitis Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229960003733 phenylephrine hydrochloride Drugs 0.000 description 1
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000010344 pupil dilation Effects 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 235000020201 recombined milk Nutrition 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 229960004540 secukinumab Drugs 0.000 description 1
- 235000020254 sheep milk Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000004341 tarsal joint Anatomy 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001745 uvea Anatomy 0.000 description 1
- 230000001982 uveitic effect Effects 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1510466.4A GB201510466D0 (en) | 2015-06-15 | 2015-06-15 | Compositions comprising bacterial strains |
| GBGB1520508.1A GB201520508D0 (en) | 2015-11-20 | 2015-11-20 | Compositions comprising bacterial strains |
| GB201606810 | 2016-04-19 | ||
| PCT/GB2016/051770 WO2016203218A1 (en) | 2015-06-15 | 2016-06-15 | Compositions comprising bacterial strains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2753779T3 true ES2753779T3 (es) | 2020-04-14 |
Family
ID=56194511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16731640T Active ES2753779T3 (es) | 2015-06-15 | 2016-06-15 | Blautia stercosis y wexlerae para la utilización en el tratamiento de enfermedades inflamatorias y autoinmunes |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US10322151B2 (enExample) |
| EP (2) | EP3240554B1 (enExample) |
| JP (3) | JP6426265B2 (enExample) |
| KR (1) | KR20180012846A (enExample) |
| CN (2) | CN108271354B (enExample) |
| AU (1) | AU2016278067B2 (enExample) |
| BR (1) | BR112017025005A2 (enExample) |
| CA (1) | CA2988661A1 (enExample) |
| CO (1) | CO2017013443A2 (enExample) |
| CY (1) | CY1122344T1 (enExample) |
| DK (1) | DK3240554T3 (enExample) |
| EA (1) | EA201890048A1 (enExample) |
| ES (1) | ES2753779T3 (enExample) |
| HR (1) | HRP20191949T1 (enExample) |
| HU (1) | HUE045754T2 (enExample) |
| IL (1) | IL255757A (enExample) |
| LT (1) | LT3240554T (enExample) |
| MA (1) | MA51639A (enExample) |
| MD (1) | MD3240554T2 (enExample) |
| MX (1) | MX2017016560A (enExample) |
| PE (1) | PE20180243A1 (enExample) |
| PL (1) | PL3240554T3 (enExample) |
| PT (1) | PT3240554T (enExample) |
| RS (1) | RS59446B1 (enExample) |
| SG (2) | SG10201912324XA (enExample) |
| SI (1) | SI3240554T1 (enExample) |
| SM (1) | SMT201900588T1 (enExample) |
| TW (2) | TWI759266B (enExample) |
| WO (1) | WO2016203218A1 (enExample) |
| ZA (1) | ZA201707772B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| ES2658310T3 (es) | 2014-12-23 | 2018-03-09 | 4D Pharma Research Limited | Una cepa de bacteroides thetaiotaomicron y su uso en la reducción de la inflamación |
| EP3193901B1 (en) | 2014-12-23 | 2018-04-04 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| PT3307288T (pt) | 2015-06-15 | 2019-10-17 | 4D Pharma Res Ltd | Composições compreendendo estirpes bacterianas |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| TWI759266B (zh) | 2015-06-15 | 2022-04-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物之用途 |
| MA55434B1 (fr) | 2015-06-15 | 2022-02-28 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| MA45287A (fr) | 2015-11-20 | 2018-08-22 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| PT3313423T (pt) | 2016-03-04 | 2019-07-10 | 4D Pharma Plc | Composições que compreendem a estirpe blautia bacteriana para tratar a hipersensibilidade visceral |
| US9999641B2 (en) | 2016-06-14 | 2018-06-19 | Vedanta Biosciences, Inc. | Treatment of clostridium difficile infection |
| PT3468573T (pt) | 2016-06-14 | 2023-10-16 | Vedanta Biosciences Inc | Tratamento de uma infeção por clostridium difficile |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| GB201621123D0 (en) * | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| WO2018187272A1 (en) | 2017-04-03 | 2018-10-11 | Gusto Global, Llc | Rational design of microbial-based biotherapeutics |
| RS61872B1 (sr) * | 2017-05-22 | 2021-06-30 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
| WO2018215782A1 (en) | 2017-05-24 | 2018-11-29 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| EP3638271B1 (en) | 2017-06-14 | 2020-10-14 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| JP6840272B2 (ja) * | 2017-06-14 | 2021-03-10 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | 細菌株を含む組成物 |
| GB201806779D0 (en) * | 2018-04-25 | 2018-06-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| RS63393B1 (sr) | 2017-06-14 | 2022-08-31 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
| WO2019046401A1 (en) * | 2017-08-29 | 2019-03-07 | Evelo Biosciences, Inc. | TREATMENT OF CANCER USING BLAUTIA STRAIN |
| WO2019075452A1 (en) * | 2017-10-13 | 2019-04-18 | Evelo Biosciences, Inc. | IDENTIFICATION OF BACTERIA FOR CANCER THERAPY |
| WO2019099482A1 (en) * | 2017-11-14 | 2019-05-23 | Evelo Biosciences, Inc. | Compositions and methods for treating disease using a blautia strain |
| WO2019115759A1 (en) * | 2017-12-14 | 2019-06-20 | Københavns Universitet | Bacterial compositions and the use thereof for the treatment or prevention of asthma or other wheezing disorders or allergy in a child |
| KR101893350B1 (ko) | 2018-02-01 | 2018-08-31 | 핸즈코퍼레이션주식회사 | 공명기 휠 |
| KR102122898B1 (ko) * | 2018-02-26 | 2020-06-15 | 주식회사 엠디헬스케어 | 블라우티아 속 세균 유래 나노소포 및 이의 용도 |
| WO2019164283A1 (ko) * | 2018-02-26 | 2019-08-29 | 주식회사 엠디헬스케어 | 블라우티아 속 세균 유래 나노소포 및 이의 용도 |
| TW202019447A (zh) | 2018-07-16 | 2020-06-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物 |
| US12161680B2 (en) | 2018-08-17 | 2024-12-10 | Vedanta Biosciences, Inc. | Methods of decreasing dysbiosis and restoring a microbiome |
| CN111304120B (zh) * | 2020-02-24 | 2021-07-23 | 浙江大学 | Blautia sp B2132菌在预防和/或治疗炎症性肠病中的应用 |
| JP2022080035A (ja) * | 2020-11-17 | 2022-05-27 | 森永乳業株式会社 | ブラウティア属細菌増殖促進用組成物 |
Family Cites Families (357)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| NL8300698A (nl) | 1983-02-24 | 1984-09-17 | Univ Leiden | Werkwijze voor het inbouwen van vreemd dna in het genoom van tweezaadlobbige planten; agrobacterium tumefaciens bacterien en werkwijze voor het produceren daarvan; planten en plantecellen met gewijzigde genetische eigenschappen; werkwijze voor het bereiden van chemische en/of farmaceutische produkten. |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| DK122686D0 (da) | 1986-03-17 | 1986-03-17 | Novo Industri As | Fremstilling af proteiner |
| FR2613624B1 (fr) | 1987-04-10 | 1990-11-23 | Roussy Inst Gustave | Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines |
| US5443826A (en) | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli |
| WO1990001335A1 (en) | 1988-08-02 | 1990-02-22 | Borody Thomas J | Treatment of gastro-intestinal disorders |
| KR100225087B1 (ko) | 1990-03-23 | 1999-10-15 | 한스 발터라벤 | 피타아제의 식물내 발현 |
| WO1991017243A1 (en) | 1990-05-09 | 1991-11-14 | Novo Nordisk A/S | A cellulase preparation comprising an endoglucanase enzyme |
| GB9107305D0 (en) | 1991-04-08 | 1991-05-22 | Unilever Plc | Probiotic |
| EP0581171B1 (en) | 1992-07-20 | 1998-02-04 | Kabushiki Kaisha Yakult Honsha | Species-specific oligonucleotides for bifidobacteria and a method of detection using the same |
| EP0673429B1 (en) | 1992-12-10 | 2002-06-12 | Dsm N.V. | Production of heterologous proteins in filamentous fungi |
| US5741665A (en) | 1994-05-10 | 1998-04-21 | University Of Hawaii | Light-regulated promoters for production of heterologous proteins in filamentous fungi |
| US5599795A (en) | 1994-08-19 | 1997-02-04 | Mccann; Michael | Method for treatment of idiopathic inflammatory bowel disease (IIBD) |
| AUPM823094A0 (en) | 1994-09-16 | 1994-10-13 | Goodman Fielder Limited | Probiotic compositions |
| AUPM864894A0 (en) | 1994-10-07 | 1994-11-03 | Borody, Thomas Julius | Treatment of bowel-dependent neurological disorders |
| RU2078815C1 (ru) | 1995-01-17 | 1997-05-10 | Московский научно-исследовательский институт эпидемиологии и микробиологии им.Г.Н.Габричевского | Штамм бактерий bifidobacterium breve, используемый для получения бактерийных лечебно-профилактических бифидосодержащих препаратов |
| JPH08259450A (ja) | 1995-03-17 | 1996-10-08 | Nichinichi Seiyaku Kk | インターフェロン産生増強剤 |
| US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
| AUPN698495A0 (en) | 1995-12-06 | 1996-01-04 | Pharma Pacific Pty Ltd | Improved therapeutic formulation and method |
| SE508045C2 (sv) | 1996-02-26 | 1998-08-17 | Arla Ekonomisk Foerening | Adhesionsinhibitorer, preparat innehållande desamma och förfarande för framställning därav |
| JP4282763B2 (ja) | 1996-03-20 | 2009-06-24 | ザ、ユニバーシティ、オブ、ニュー、サウス、ウェイルズ | 消化管内の微生物個体数の変更 |
| AUPN881396A0 (en) | 1996-03-20 | 1996-04-18 | Arnott's Biscuits Limited | Enhancement of microbial colonization of the gastrointestinal tract |
| JP4263241B2 (ja) | 1996-03-27 | 2009-05-13 | ノボザイムス アクティーゼルスカブ | アルカリプロテアーゼを欠失した糸状真菌 |
| US6033864A (en) | 1996-04-12 | 2000-03-07 | The Regents Of The University Of California | Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens |
| WO1998043081A1 (en) | 1997-03-26 | 1998-10-01 | Ligand Pharmaceuticals Incorporated | Treatment of gastrointestinal disease with ppar modulators |
| SE511524C2 (sv) | 1997-06-02 | 1999-10-11 | Essum Ab | Lactobacillus casei rhamnosus-stam samt farmaceutisk beredning för bekämpning av patogena tarmbakterier |
| US5925657A (en) | 1997-06-18 | 1999-07-20 | The General Hospital Corporation | Use of PPARγ agonists for inhibition of inflammatory cytokine production |
| AUPO758297A0 (en) | 1997-06-27 | 1997-07-24 | Rowe, James Baber | Control of acidic gut syndrome |
| US5951977A (en) | 1997-10-14 | 1999-09-14 | The United States Of America, As Represented By The Secretary Of Agriculture | Competitive exclusion culture for swine |
| IT1298918B1 (it) | 1998-02-20 | 2000-02-07 | Mendes Srl | Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche |
| DE19826928A1 (de) | 1998-06-17 | 1999-12-23 | Novartis Consumer Health Gmbh | Arzneimittel, lebensfähige anaerobe Bakterien enthaltend, die die Sulfatreduktion sulfatreduzierender Bakterien hemmen |
| ID29150A (id) | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | Penggunaan lactobacillus salivarius |
| US7090973B1 (en) | 1999-04-09 | 2006-08-15 | Oscient Pharmaceuticals Corporation | Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics |
| US6417212B1 (en) | 1999-08-27 | 2002-07-09 | Eli Lilly & Company | Modulators of peroxisome proliferator activated receptors |
| AU777210C (en) | 2000-02-08 | 2005-08-04 | Dsm Ip Assets B.V. | Use of acid-stable subtilisin proteases in animal feed |
| FR2808689B1 (fr) | 2000-05-11 | 2004-09-03 | Agronomique Inst Nat Rech | Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs |
| US20020013270A1 (en) | 2000-06-05 | 2002-01-31 | Bolte Ellen R. | Method for treating a mental disorder |
| AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| AU2002226984A1 (en) | 2000-11-27 | 2002-06-03 | Astrazeneca Ab | Method for studying the effects of commensal microflora on mammalian intestine and treatments of gastrointestinal-associated disease based thereon |
| DE10101793A1 (de) | 2001-01-17 | 2002-08-01 | Manfred Nilius | Verwendung von SLPI zur Behandlung chronisch-entzündlicher Darmerkrankungen |
| EP1227152A1 (en) | 2001-01-30 | 2002-07-31 | Société des Produits Nestlé S.A. | Bacterial strain and genome of bifidobacterium |
| KR100437497B1 (ko) | 2001-03-07 | 2004-06-25 | 주식회사 프로바이오닉 | 로타바이러스 및 유해 미생물 억제 활성을 가지는 신규내산성 락토바실러스 루테리 프로바이오-16 및 이를함유하는 생균활성제 |
| EP1243273A1 (en) | 2001-03-22 | 2002-09-25 | Societe Des Produits Nestle S.A. | Composition comprising a prebiotic for decreasing infammatory process and abnormal activation of non-specific immune parameters |
| EP1379552B2 (en) | 2001-04-20 | 2014-11-19 | The Institute for Systems Biology | Toll-like receptor 5 ligands and methods of use |
| EP1260227A1 (en) | 2001-05-23 | 2002-11-27 | Societe Des Produits Nestle S.A. | Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative bacteria, potential pathogenic gram-positive bacteria |
| US20030092163A1 (en) | 2001-07-26 | 2003-05-15 | Collins John Kevin | Probiotic bifidobacterium strains |
| EP1432426A2 (en) | 2001-09-05 | 2004-06-30 | ACTIAL Farmaceutica Lda. | USE OF UNMETHYLATED CpG |
| GB0127916D0 (en) | 2001-11-21 | 2002-01-16 | Rowett Res Inst | Method |
| US20050037955A1 (en) | 2001-11-27 | 2005-02-17 | Hooper Laura Virginia | Therapeutic protein and treatments |
| DK1581119T3 (da) | 2001-12-17 | 2013-05-13 | Corixa Corp | Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme |
| US7101565B2 (en) | 2002-02-05 | 2006-09-05 | Corpak Medsystems, Inc. | Probiotic/prebiotic composition and delivery method |
| DE10206995B4 (de) | 2002-02-19 | 2014-01-02 | Orthomol Pharmazeutische Vertriebs Gmbh | Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika |
| JP2003261453A (ja) | 2002-03-11 | 2003-09-16 | Nippon Berumu Kk | Ｅ．フェカリスからなる抗腫瘍剤及び放射線防護剤 |
| DK1565547T4 (da) | 2002-06-28 | 2013-01-14 | Biosearch S A | Probiotiske stammer, en fremgangsmåde til selektion deraf, præparater deraf samt anvendelse deraf |
| US20040005304A1 (en) | 2002-07-08 | 2004-01-08 | Mak Wood, Inc. | Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions |
| GB0307026D0 (en) | 2003-03-27 | 2003-04-30 | Rowett Res Inst | Bacterial supplement |
| EP1481681A1 (en) | 2003-05-30 | 2004-12-01 | Claudio De Simone | Lactic acid bacteria combination and compositions thereof |
| GB0316915D0 (en) | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
| WO2005007834A1 (en) | 2003-07-23 | 2005-01-27 | Probionic Corp. | Acid tolerant probiotic lactobacillus plantarum probio-38 that can suppress the growth of pathogenic microorganism and tge coronavirus |
| US7485325B2 (en) | 2003-08-06 | 2009-02-03 | Gayle Dorothy Swain | Animal food supplement compositions and methods of use |
| JP4683881B2 (ja) | 2003-08-27 | 2011-05-18 | 有限会社アーク技研 | 抗腫瘍活性剤 |
| US8192733B2 (en) | 2003-08-29 | 2012-06-05 | Cobb & Associates | Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions |
| WO2005030133A2 (en) | 2003-09-22 | 2005-04-07 | Yale University | Treatment with agonists of toll-like receptors |
| GB0323039D0 (en) | 2003-10-01 | 2003-11-05 | Danisco | Method |
| NZ546664A (en) | 2003-10-24 | 2009-04-30 | Nutricia Nv | Synbiotic composition for infants |
| US20050239706A1 (en) | 2003-10-31 | 2005-10-27 | Washington University In St. Louis | Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject |
| RU2407784C2 (ru) | 2003-12-17 | 2010-12-27 | Н.В. Нютрисиа | Пробиотический штамм lactobacillus casei, продуцирующий молочную кислоту, применение штамма для приготовления питательной композиции для лечения или профилактики легочной дисфункции, питательная композиция и способ ее получения, лекарственное средство для лечения или профилактики хронической обструктивной болезни легких у субъекта и применение штамма для приготовления лекарственного средства, контейнер |
| ES2235642B2 (es) | 2003-12-18 | 2006-03-01 | Gat Formulation Gmbh | Proceso de multi-microencapsulacion continuo para la mejora de la estabilidad y almacenamiento de ingredientes biologicamente activos. |
| CA2557800A1 (en) | 2004-03-22 | 2005-10-06 | Yossef Raviv | Cellular and viral inactivation |
| WO2005107381A2 (en) | 2004-05-07 | 2005-11-17 | Hans-Gustaf Ljunggren | Use of flagellin as an adjuvant for vaccine |
| US7638513B2 (en) | 2004-06-02 | 2009-12-29 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| PE20060426A1 (es) | 2004-06-02 | 2006-06-28 | Schering Corp | DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa |
| PL1765391T3 (pl) | 2004-06-07 | 2013-08-30 | Qu Biologics Inc | Kompozycje bakteryjne do leczenia nowotworów |
| EP1629850B2 (en) | 2004-08-24 | 2013-05-22 | N.V. Nutricia | Nutritional composition comprising indigestible transgalactooligosaccharides and digestible galactose saccharides |
| US20060062773A1 (en) | 2004-09-21 | 2006-03-23 | The Procter & Gamble Company | Compositions for maintaining and restoring normal gastrointestinal flora |
| KR100468522B1 (ko) | 2004-10-12 | 2005-01-31 | 주식회사 프로바이오닉 | 코로나바이러스와 돼지 써코바이러스 2형의 생육을 억제하는 신규한 내산성 프로바이오틱 엔테로코커스훼시움 프로바이오-63 |
| US20060115465A1 (en) | 2004-10-29 | 2006-06-01 | Macfarlane George | Treatment of gastrointestinal disorders |
| ITMI20042189A1 (it) | 2004-11-16 | 2005-02-16 | Anidral Srl | Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale |
| PL2805625T5 (pl) | 2005-02-28 | 2023-03-13 | N.V. Nutricia | Kompozycja odżywcza z prebiotykami i probiotykami |
| EP1861490A4 (en) | 2005-03-23 | 2010-11-17 | Univ St Louis | USE OF ARRAYS TO MODULATE NUTRIENT CAPTURE FUNCTIONS BY THE GASTROINTESTINAL MICROBIOTE |
| US20090233888A1 (en) | 2005-03-23 | 2009-09-17 | Usc Stevens, University Of Southern California | Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth |
| JP2006265212A (ja) | 2005-03-25 | 2006-10-05 | Institute Of Physical & Chemical Research | Ｉｌ−２１産生誘導剤 |
| US20100233312A9 (en) | 2005-04-11 | 2010-09-16 | The Procter & Gamble Company | Compositions comprising probiotic and sweetener components |
| EP1714660A1 (en) | 2005-04-21 | 2006-10-25 | N.V. Nutricia | Uronic acid and probiotics |
| ES2382873T3 (es) | 2005-04-26 | 2012-06-14 | Teagasc, The Agriculture And Food Development Authority | Composición probiótica adecuada para animales |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| US7572474B2 (en) | 2005-06-01 | 2009-08-11 | Mead Johnson Nutrition Company | Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants |
| US8075934B2 (en) | 2008-10-24 | 2011-12-13 | Mead Johnson Nutrition Company | Nutritional composition with improved digestibility |
| JP2007084533A (ja) | 2005-08-24 | 2007-04-05 | Prima Meat Packers Ltd | 免疫応答調節組成物及び該組成物を有効成分とする食品 |
| US7625704B2 (en) | 2005-08-31 | 2009-12-01 | Fred Hutchinson Cancer Research Center | Methods and compositions for identifying bacteria associated with bacteria vaginosis |
| CN101296706B (zh) | 2005-09-01 | 2011-11-30 | 先灵公司 | Il-23和il-17拮抗剂治疗自身免疫性眼部炎性疾病的用途 |
| WO2007035057A1 (en) | 2005-09-23 | 2007-03-29 | Gwangju Institute Of Science And Technology | Composition for preventing or treating artritis comprising lactic acid bacteria and collangen as active ingredients |
| EP1776877A1 (en) | 2005-10-21 | 2007-04-25 | N.V. Nutricia | Method for stimulating the intestinal flora |
| JP5030960B2 (ja) | 2005-10-24 | 2012-09-19 | ネステク ソシエテ アノニム | 食物繊維製剤及び投与方法 |
| JP2007116991A (ja) | 2005-10-28 | 2007-05-17 | Eternal Light General Institute Inc | 機能性食品 |
| US7767420B2 (en) | 2005-11-03 | 2010-08-03 | Momenta Pharmaceuticals, Inc. | Heparan sulfate glycosaminoglycan lyase and uses thereof |
| AU2006320604A1 (en) | 2005-12-01 | 2007-06-07 | Schering Corporation | Compounds for the treatment of inflammatory disorders and microbial diseases |
| US8889149B2 (en) | 2006-02-16 | 2014-11-18 | Wayne State University | Use of flagellin to prevent and treat gram negative bacterial infection |
| US20080260898A1 (en) | 2006-03-17 | 2008-10-23 | Marko Stojanovic | Compositions comprising probiotic and sweetener components |
| JP5031249B2 (ja) | 2006-03-22 | 2012-09-19 | 学校法人北里研究所 | 炎症抑制作用のある菌体含有組成物 |
| EP2040724B1 (en) | 2006-05-18 | 2011-10-05 | Biobalance Llc | Biotherapeutic compositions comprising probiotic escherichia coli and metronidazole and uses thereof |
| MY147954A (en) | 2006-05-26 | 2013-02-15 | Nestec Sa | Methods of use and nutritional compositions of touchi extract |
| WO2007140613A1 (en) | 2006-06-06 | 2007-12-13 | Mcgill University | Fermented milk product and use thereof |
| TW200819540A (en) | 2006-07-11 | 2008-05-01 | Genelux Corp | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders |
| US8691213B2 (en) | 2006-08-04 | 2014-04-08 | SHS International | Protein free formula |
| WO2008031438A2 (en) | 2006-09-13 | 2008-03-20 | Region Hovedstaden V/Gentofte Hospital | Treatment of asthma, eczema and/or allergy using non-pathogenic organisms |
| US20080069861A1 (en) | 2006-09-19 | 2008-03-20 | National Starch And Chemical Investment Holding Corporation | Probiotic/Non-Probiotic Combinations |
| ES2744816T3 (es) | 2006-10-27 | 2020-02-26 | Capsugel Belgium Nv | Cápsulas duras de hidroxipropil metil celulosa y proceso de fabricación |
| WO2008053444A2 (en) | 2006-11-01 | 2008-05-08 | The Procter & Gamble Company | Treating a respiratory condition with bifidobacterium |
| EP1920781B1 (en) | 2006-11-10 | 2015-03-04 | Glycotope GmbH | Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors |
| WO2008064489A1 (en) | 2006-12-01 | 2008-06-05 | Mcmaster University | Probiotics to inhibit inflammation |
| WO2008076696A2 (en) | 2006-12-18 | 2008-06-26 | Washington University In St. Louis | The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder |
| DE102006062250A1 (de) | 2006-12-22 | 2008-06-26 | Roland Saur-Brosch | Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden |
| WO2008083157A2 (en) | 2006-12-29 | 2008-07-10 | Washington University In St. Louis | Altering pgc-1alapha, ampk, fiaf, or the gastrointestinal microbiota as a means to modulate body fat and/or weight loss in a subject |
| JP2008195635A (ja) | 2007-02-09 | 2008-08-28 | Crossfield Bio Inc | 馬用乳酸菌製剤 |
| CN105796607A (zh) | 2007-02-28 | 2016-07-27 | Mjn 美国控股有限责任公司 | 用于儿童或婴幼儿的含有灭活益生菌的产品 |
| KR20090127180A (ko) | 2007-03-28 | 2009-12-09 | 앨러멘터리 헬스 리미티드 | 프로바이오틱 비피도박테리움 스트레인 |
| BRPI0810087A2 (pt) | 2007-03-28 | 2014-10-21 | Alimentary Health Ltd | Cepas de bifidobacterium probióticas |
| US20080299098A1 (en) | 2007-04-24 | 2008-12-04 | Chea-Yun Se | Broad-Spectrum Antibacterial and Antifungal Activity of Lactobacillus Johnsonii D115 |
| EP1997499A1 (en) | 2007-05-31 | 2008-12-03 | Puleva Biotech, S.A. | Mammalian milk microorganisms, compositions containing them and their use for the treatment of mastitis |
| EP1997907A1 (en) | 2007-06-01 | 2008-12-03 | Friesland Brands B.V. | Bifidobacteria |
| EP1997905A1 (en) | 2007-06-01 | 2008-12-03 | Friesland Brands B.V. | Nucleic acid amplification |
| EP1997906A1 (en) | 2007-06-01 | 2008-12-03 | Friesland Brands B.V. | Lactobacillus |
| WO2008153377A1 (en) | 2007-06-15 | 2008-12-18 | N.V. Nutricia | Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide |
| WO2009000899A1 (en) | 2007-06-27 | 2008-12-31 | Laboratorios Ordesa, S.L. | A novel strain of bifidobacterium and active peptides against rotavirus infections |
| HUP0700552A2 (en) | 2007-08-27 | 2009-03-30 | Janos Dr Feher | Method and composition inhibiting inflammation |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| WO2009043856A2 (en) | 2007-10-01 | 2009-04-09 | University College Cork, National University Of Ireland, Cork | Modulation of tissue fatty acid composition of a host by human gut bacteria |
| EP2203551B1 (en) | 2007-10-20 | 2013-08-21 | Université de Liège | Bifidobacterial species |
| ES2473625T3 (es) | 2007-10-26 | 2014-07-07 | Brenda E. Moore | Composición probi�tica y métodos para inducir y mantener la pérdida de peso |
| ES2567079T3 (es) | 2007-11-02 | 2016-04-19 | Momenta Pharmaceuticals, Inc. | Composiciones de polisacáridos que no son anticoagulantes |
| EP2065048A1 (en) | 2007-11-30 | 2009-06-03 | Institut Pasteur | Use of a L. casei strain, for the preparation of a composition for inhibiting mast cell activation |
| EP2217253B1 (en) | 2007-12-07 | 2011-06-29 | N.V. Nutricia | Bifidobacterium for dust mite allergy |
| WO2009079564A2 (en) | 2007-12-17 | 2009-06-25 | Emory University | Immunogenic compositions and methods of use thereof |
| ES2343499B1 (es) | 2007-12-24 | 2011-06-10 | Consejo Superior De Investigaciones Cientificas | Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten. |
| RU2010132283A (ru) | 2008-02-06 | 2012-03-20 | Дзе Проктер Энд Гэмбл Компани (US) | Композиции, способы и наборы для повышения иммунного ответа на респираторное заболевание |
| EP2103226A1 (en) | 2008-03-18 | 2009-09-23 | Friesland Brands B.V. | Long-life probiotic food product |
| SG190562A1 (en) | 2008-04-18 | 2013-06-28 | Vaxinnate Corp | Deletion mutants of flagellin and methods of use |
| AR071787A1 (es) | 2008-05-13 | 2010-07-14 | Glycotope Gmbh | Procedimiento de fermentacion, alimento fermentado producido por dicho procedimiento y auxiliar de procesamiento |
| MX2008006546A (es) | 2008-05-21 | 2009-11-23 | Sigma Alimentos Sa De Cv | Bifidobacteria productora de ácido fólico, composición alimenticia y uso de la bifidobacteria. |
| CN101590081A (zh) | 2008-05-28 | 2009-12-02 | 青岛东海药业有限公司 | 凸腹真杆菌和两形真杆菌制剂及其应用 |
| CN102940652B (zh) | 2008-05-28 | 2015-03-25 | 青岛东海药业有限公司 | 两形真杆菌制剂及其应用 |
| US8586029B2 (en) | 2008-06-04 | 2013-11-19 | Trustees Of Dartmouth College | Prevention or treatment of immune-relevant disease by modification of microfloral populations |
| EP2133088A3 (en) | 2008-06-09 | 2010-01-27 | Nestec S.A. | Rooibos and inflammation |
| WO2009151315A1 (en) | 2008-06-13 | 2009-12-17 | N.V. Nutricia | Nutritional composition for infants delivered via caesarean section |
| WO2009154463A2 (en) | 2008-06-20 | 2009-12-23 | Stichting Top Institute Food And Nutrition | Butyrate as a medicament to improve visceral perception in humans |
| EP2138186A1 (en) | 2008-06-24 | 2009-12-30 | Nestec S.A. | Probiotics, secretory IgA and inflammation |
| WO2010002241A1 (en) | 2008-06-30 | 2010-01-07 | N.V. Nutricia | Nutritional composition for infants delivered via caesarean section |
| KR101017448B1 (ko) | 2008-09-18 | 2011-02-23 | 주식회사한국야쿠르트 | 대장의 건강 증진 효능을 갖는 비피도박테리움 롱검 에이취와이8004 및 이를 유효성분으로 함유하는 제품 |
| US8137718B2 (en) | 2008-09-19 | 2012-03-20 | Mead Johnson Nutrition Company | Probiotic infant products |
| US20100074870A1 (en) | 2008-09-19 | 2010-03-25 | Bristol-Myers Squibb Company | Probiotic infant products |
| KR101057357B1 (ko) | 2008-09-22 | 2011-08-17 | 광주과학기술원 | 유산균 및 콜라겐을 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물 및 식품 조성물 |
| WO2010036876A2 (en) | 2008-09-25 | 2010-04-01 | New York University | Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| US10369204B2 (en) | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| RU2509478C2 (ru) | 2008-12-05 | 2014-03-20 | Нестек С.А. | Пробиотическая композиция, предназначенная для младенцев с низкой массой тела при рождении |
| WO2010069737A1 (en) | 2008-12-19 | 2010-06-24 | Nestec S.A. | Prevention and treatment of rotavirus diarrhoea |
| IT1392672B1 (it) | 2009-01-12 | 2012-03-16 | Wyeth Consumer Healthcare S P A | Composizioni comprendenti componenti probiotici e prebiotici e sali minerali, con lactoferrina |
| PE20160653A1 (es) | 2009-03-05 | 2016-07-24 | Abbvie Inc | Proteinas de union a il-17 |
| JP5710876B2 (ja) | 2009-03-26 | 2015-04-30 | クロスフィールドバイオ株式会社 | 新規ビフィドバクテリウム属微生物およびその利用 |
| KR101783383B1 (ko) | 2009-05-07 | 2017-09-29 | 테이트 ＆ 라일 인그레디언츠 프랑스 에스에이에스 | 알파-(1,2)-분지형 알파-(1,6) 올리고덱스트란을 제조하기 위한 조성물 및 방법 |
| CA2761573A1 (en) | 2009-05-11 | 2010-11-18 | Nestec S.A. | Bifidobacterium longum ncc2705 (cncm i-2618) and immune disorders |
| EP2251020A1 (en) | 2009-05-11 | 2010-11-17 | Nestec S.A. | Short-time high temperature treatment generates microbial preparations with anti-inflammatory profiles |
| EP2251022A1 (en) | 2009-05-11 | 2010-11-17 | Nestec S.A. | Non-replicating micro-organisms and their immune boosting effect |
| KR20100128168A (ko) | 2009-05-27 | 2010-12-07 | 중앙대학교 산학협력단 | 공액 리놀레산 생산능이 우수한 신규한 균주 |
| US20100311686A1 (en) | 2009-06-03 | 2010-12-09 | Kasper Lloyd H | Nutraceutical composition and methods for preventing or treating multiple sclerosis |
| WO2010143940A1 (en) | 2009-06-12 | 2010-12-16 | N.V. Nutricia | Synergistic mixture of beta-galacto-oligosaccharides with beta-1,3 and beta-1,4/1,6 linkages |
| WO2010147714A1 (en) | 2009-06-16 | 2010-12-23 | The Trustees Of Columbia University In The City Of New York | Autism-associated biomarkers and uses thereof |
| WO2011005756A1 (en) | 2009-07-06 | 2011-01-13 | Puretech Ventures, Llc | Delivery of agents targeted to microbiota niches |
| US20120129794A1 (en) | 2009-07-24 | 2012-05-24 | Dowd Scot E | Apparati, methods, and compositions for universal microbial diagnosis, detection, quantification, and specimen-targeted therapy |
| AU2010285128B2 (en) | 2009-08-18 | 2015-05-14 | Société des Produits Nestlé S.A. | A nutritional composition comprising Bifidobacterium longum strains and reducing food allergy symtoms, especially in infants and children |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| PL2480255T3 (pl) | 2009-09-23 | 2018-07-31 | Thomas Julius Borody | Terapia przewlekłych zakażeń jelitowych |
| EP2308498A1 (en) | 2009-09-30 | 2011-04-13 | Nestec S.A. | Administration of Bifidobacterium breve during infancy to prevent inflammation later in life |
| WO2011043654A1 (en) | 2009-10-05 | 2011-04-14 | Aak Patent B.V. | Methods for diagnosing irritable bowel syndrome |
| EP3144004A1 (en) | 2009-10-06 | 2017-03-22 | Scott Dorfner | Antibiotic formulations providing reduced gastrointestinal side effects and clostridium difficile infection relapse, and related methods |
| RU2546251C2 (ru) | 2009-11-11 | 2015-04-10 | Алиментари Хелс Лимитед | Пробиотический штамм бифидобактерий |
| CN102651973A (zh) | 2009-12-18 | 2012-08-29 | 希尔氏宠物营养品公司 | 包含益生菌的宠物食物组合物及其制造和使用方法 |
| US20150104418A1 (en) | 2014-12-18 | 2015-04-16 | Microbios, Inc. | Bacterial composition |
| FR2955774A1 (fr) | 2010-02-02 | 2011-08-05 | Aragan | Preparation destinee a traiter l'exces ponderal et les desordres associes et applications de ladite preparation |
| NL2004201C2 (en) | 2010-02-05 | 2011-08-08 | Friesland Brands Bv | Use of sialyl oligosaccharides to modulate the immune system. |
| NL2004200C2 (en) | 2010-02-05 | 2011-08-08 | Friesland Brands Bv | Use of sialyl oligosaccharides in weight management. |
| IT1398553B1 (it) | 2010-03-08 | 2013-03-01 | Probiotical Spa | Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario. |
| JP5737646B2 (ja) | 2010-03-24 | 2015-06-17 | 森下仁丹株式会社 | 抗アレルギー剤 |
| WO2011121379A1 (en) | 2010-03-30 | 2011-10-06 | Assistance Publique - Hopitaux De Paris | Use of bifidobacteria for preventing allergy in breastfed infants |
| US8951512B2 (en) | 2010-05-04 | 2015-02-10 | New York University | Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota |
| WO2011149335A1 (en) | 2010-05-25 | 2011-12-01 | N.V. Nutricia | Immune imprinting nutritional composition |
| WO2011153226A2 (en) | 2010-06-01 | 2011-12-08 | Moore Research Enterprises Llc | Cellular constituents from bacteroides, compositions thereof, and therapeutic methods employing bacteroides or cellular constituents thereof |
| WO2011151941A1 (ja) | 2010-06-04 | 2011-12-08 | 国立大学法人東京大学 | 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物 |
| TWI417054B (zh) | 2010-06-15 | 2013-12-01 | Jen Shine Biotechnology Co Ltd | 新穎糞腸球菌ｌｊｓ－０１及其益生用途 |
| EP2397145A1 (en) | 2010-06-18 | 2011-12-21 | Nestec S.A. | L. johnsonii La1, B. longum NCC2705 and immune disorders |
| FR2962045B1 (fr) | 2010-07-05 | 2012-08-17 | Bifinove | Complexe macromoleculaire d'origine bacterienne et utilisation dudit complexe moleculaire pour prevenir et traiter les rhumatismes inflammatoires |
| TWI401086B (zh) | 2010-07-20 | 2013-07-11 | Univ China Medical | 胚芽乳酸桿菌及其用途 |
| ES2645509T3 (es) | 2010-07-26 | 2017-12-05 | Qu Biologics Inc | Composiciones antiinflamatorias inmunogénicas |
| BR112013002667B1 (pt) | 2010-08-04 | 2020-02-04 | Thomas Julius Borody | composições para transplante da flora intestinal e métodos para fazê-las e usá-las e dispositivos para administrá-las |
| US9386793B2 (en) | 2010-08-20 | 2016-07-12 | New York University | Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota |
| KR101250463B1 (ko) | 2010-10-12 | 2013-04-15 | 대한민국 | 신생아 분변에서 분리한 내산소성 비피도박테리움 롱검 비피더스 유산균 및 이를 이용한 프로바이오틱 조성물 |
| CA2815259A1 (en) | 2010-10-27 | 2012-05-03 | Quantibact A/S | Capture of target dna and rna by probes comprising intercalator molecules |
| CN102031235B (zh) | 2010-11-09 | 2012-07-25 | 中国农业大学 | 一种粪肠球菌anse228及其应用 |
| EP2455092A1 (en) | 2010-11-11 | 2012-05-23 | Nestec S.A. | Non-replicating probiotic micro-organisms protect against upper respiratory tract infections |
| WO2012071380A1 (en) | 2010-11-24 | 2012-05-31 | Oragenics, Inc. | Use of bacteria to treat and prevent respiratory infections |
| CN102093967B (zh) | 2010-12-02 | 2013-01-30 | 中国农业科学院特产研究所 | 一株水貂源屎肠球菌及其应用 |
| ES2389547B1 (es) | 2010-12-07 | 2013-08-08 | Consejo Superior De Investigaciones Científicas (Csic) | Bifidobacterium cect 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas. |
| SG191830A1 (en) | 2011-01-10 | 2013-08-30 | Cleveland Biolabs Inc | Use of toll-like receptor agonist for treating cancer |
| PT2481299T (pt) | 2011-01-31 | 2017-03-08 | Synformulas Gmbh | Estirpes de bifidobacterium bifidum para aplicação em doenças gastrointestinais |
| JP5840368B2 (ja) | 2011-02-02 | 2016-01-06 | カルピス株式会社 | 関節炎予防改善用物質 |
| US8927252B2 (en) | 2011-02-09 | 2015-01-06 | Lavivo Ab | Synbiotic compositions for restoration and reconstitution of gut microbiota |
| EP3610881A1 (en) | 2011-03-09 | 2020-02-19 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
| BRPI1100857A2 (pt) | 2011-03-18 | 2013-05-21 | Alexandre Eduardo Nowill | agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real |
| WO2012140636A1 (en) | 2011-04-11 | 2012-10-18 | Alimentary Health Limited | A probiotic formulation |
| WO2012142605A1 (en) | 2011-04-15 | 2012-10-18 | Samaritan Health Services | Rapid recolonization deployment agent |
| BR112013026929A2 (pt) | 2011-04-20 | 2016-12-27 | Mico Bio Inc | composição e método para intensificação de uma resposta imune |
| JP6129821B2 (ja) | 2011-05-13 | 2017-05-17 | グリコシン リミテッド ライアビリティー カンパニー | プレバイオティクスとしての、精製された２’−フコシルラクトース、３−フコシルラクトース、およびラクトジフコテトラオースの使用 |
| KR20120133133A (ko) | 2011-05-30 | 2012-12-10 | 한국 한의학 연구원 | 생약 추출물 또는 이의 유산균 발효물을 포함하는 호흡기 질환의 예방 또는 치료용 조성물 |
| US20140171339A1 (en) | 2011-06-06 | 2014-06-19 | The University Of North Carolina At Chapel Hill | Methods and kits for detecting adenomas, colorectal cancer, and uses thereof |
| GB201110095D0 (en) | 2011-06-15 | 2011-07-27 | Danisco | Method of treatment |
| JP2013005759A (ja) | 2011-06-24 | 2013-01-10 | Kyodo Milk Industry Co Ltd | マウス腸内菌叢の推測方法 |
| WO2013005836A1 (ja) | 2011-07-07 | 2013-01-10 | 長岡香料株式会社 | フルクトース吸収阻害剤 |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| WO2013008102A2 (en) | 2011-07-14 | 2013-01-17 | R.E.D. Laboratories N.V../ S.A. | Methods and compositions for evaluating and/or treating chronic immune diseases |
| US20130022575A1 (en) | 2011-07-19 | 2013-01-24 | Microbial Rx | Systems and methods of replacing intestinal flora |
| CN102304483A (zh) | 2011-08-12 | 2012-01-04 | 北京金泰得生物科技股份有限公司 | 一株饲用屎肠球菌及其应用 |
| KR101261872B1 (ko) | 2011-08-23 | 2013-05-14 | 대한민국 (식품의약품안전처장) | 장내 미생물 효소복합체 및 이의 제조방법 |
| CA2848762C (en) | 2011-09-14 | 2021-07-27 | Queen's University At Kingston | Method for treatment of disorders of the gastrointestinal system |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| AU2012322979B2 (en) | 2011-10-11 | 2017-02-02 | Achim Biotherapeutics Ab | Composition comprising anaerobically cultivated human intestinal microbiota |
| CN103082292B (zh) | 2011-11-02 | 2015-03-04 | 深圳华大基因研究院 | 罗斯氏菌(Roseburia)在治疗和预防肥胖相关疾病中的应用 |
| CN102373172B (zh) | 2011-11-03 | 2013-03-20 | 北京龙科方舟生物工程技术有限公司 | 一株屎肠球菌及其应用 |
| EP3569690B1 (en) * | 2011-12-01 | 2024-08-28 | The University of Tokyo | Human-derived bacteria that induce proliferation or accumulation of regulatory t cells |
| ES2408279B1 (es) | 2011-12-15 | 2014-09-09 | Universidad De Las Palmas De Gran Canaria | Bacteria acido láctica probiótica |
| ITBG20120010A1 (it) | 2012-02-24 | 2013-08-25 | Milano Politecnico | Dispositivo per l'addestramento chirurgico |
| ITMI20120471A1 (it) | 2012-03-26 | 2013-09-27 | Giovanni Mogna | Composizione a base di ceppi di batteri bifidobacterium longum in grado di aiutare il prolungamento della vita |
| JP5792105B2 (ja) | 2012-03-27 | 2015-10-07 | 森永乳業株式会社 | ラクト−ｎ−ビオースｉの製造方法 |
| JP6201982B2 (ja) | 2012-03-30 | 2017-09-27 | 味の素株式会社 | 糖尿病誘起細菌 |
| WO2013154826A2 (en) | 2012-04-11 | 2013-10-17 | Nestec Sa | Methods for diagnosing impending diarrhea |
| US20150265661A1 (en) | 2012-04-13 | 2015-09-24 | Trustees Of Boston College | Prebiotic effect of sialyllactose |
| GB201206599D0 (en) | 2012-04-13 | 2012-05-30 | Univ Manchester | Probiotic bacteria |
| EP3686284A1 (en) | 2012-05-18 | 2020-07-29 | Genome Research Limited | Methods and groups |
| ES2436251B1 (es) | 2012-05-25 | 2014-10-08 | Consejo Superior De Investigaciones Científicas (Csic) | Bacteroides cect 7771 y su uso en la prevención y tratamiento de sobrepeso, obesidad y alteraciones metabólicas e inmunológicas. |
| JP6436580B2 (ja) | 2012-06-04 | 2018-12-12 | ガウラブ アグラーワル， | クローン病および関連する状態および感染症を処置するための組成物および方法 |
| CN102743420A (zh) | 2012-06-06 | 2012-10-24 | 上海交通大学 | 改善肠道菌群结构的方法及应用 |
| US9676847B2 (en) | 2012-06-25 | 2017-06-13 | Orega Biotech | IL-17 antagonist antibodies |
| BR112015001884B1 (pt) | 2012-07-31 | 2020-12-01 | Société des Produits Nestlé S.A. | composição nutricional para promover a saúde musculoesquelética em pacientes com doença inflamatória intestinal (ibd), seu uso, e formulação farmacêutica, formulação nutricional, formulação de alimentação por tubo, suplemento alimentar, alimento funcional ou produto de bebida |
| US20150211053A1 (en) | 2012-08-01 | 2015-07-30 | Bgi-Shenzhen | Biomarkers for diabetes and usages thereof |
| US10220089B2 (en) | 2012-08-29 | 2019-03-05 | California Institute Of Technology | Diagnosis and treatment of autism spectrum disorder |
| JP2015531770A (ja) | 2012-08-29 | 2015-11-05 | サリックス ファーマシューティカルズ，インコーポレイテッド | 緩下剤組成物、ならびに便秘および関連胃腸疾患および症状を処置するための方法 |
| WO2014043593A2 (en) | 2012-09-13 | 2014-03-20 | Massachusetts Institute Of Technology | Programmable drug delivery profiles of tumor-targeted bacteria |
| KR101473058B1 (ko) | 2012-09-19 | 2014-12-16 | 주식회사 쎌바이오텍 | 과민성 대장 증후군 예방 또는 치료용 조성물 |
| CN103652322B (zh) | 2012-09-21 | 2016-02-10 | 临沂思科生物科技有限公司 | 一种含乳酸菌的复合益生菌饲料添加剂的制备方法 |
| WO2014053608A1 (en) | 2012-10-03 | 2014-04-10 | Metabogen Ab | Identification of a person having risk for atherosclerosis and associated diseases by the person's gut microbiome and the prevention of such diseases |
| FR2997091B1 (fr) | 2012-10-22 | 2016-05-06 | Fond Mediterranee Infection | Utilisation d'un compose antioxydant pour la culture de bacteries sensibles a la tension en oxygene |
| WO2014067976A1 (en) | 2012-10-30 | 2014-05-08 | Nestec S.A. | Compositions comprising microparticles and probiotics to deliver a synergistic immune effect |
| US9839657B2 (en) | 2012-10-30 | 2017-12-12 | Deerland Enzymes, Inc. | Prebiotic compositions comprising one or more types of bacteriophage |
| US20150283144A1 (en) | 2012-11-01 | 2015-10-08 | Rijksuniversiteit Groningen | Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract |
| WO2014075745A1 (en) | 2012-11-19 | 2014-05-22 | Université Catholique de Louvain | Use of akkermansia for treating metabolic disorders |
| CN104955466A (zh) | 2012-11-23 | 2015-09-30 | 赛里斯治疗公司 | 协同细菌组合物和其制造方法和用途 |
| US8906668B2 (en) * | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| KR20150103012A (ko) | 2012-11-26 | 2015-09-09 | 토마스 줄리어스 보로디 | 분변 마이크로바이오타 복원을 위한 조성물 및 이의 제조 및 사용 방법 |
| EP2931898B1 (en) | 2012-12-12 | 2016-03-09 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| ES2576126T3 (es) | 2012-12-12 | 2016-07-05 | The Broad Institute, Inc. | Modificación por tecnología genética y optimización de sistemas, métodos y composiciones enzimáticas mejorados para la manipulación de secuencias |
| KR20150105956A (ko) | 2012-12-12 | 2015-09-18 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작 및 치료적 적용을 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화 |
| US20140193464A1 (en) | 2013-01-08 | 2014-07-10 | Imagilin Technology, Llc | Effects of probiotics on humans and animals under environmental or biological changes |
| KR102222273B1 (ko) * | 2013-02-04 | 2021-03-08 | 세레스 테라퓨틱스, 인코포레이티드 | 조성물 및 방법 |
| WO2014121304A1 (en) * | 2013-02-04 | 2014-08-07 | Seres Health, Inc. | Compositions and methods |
| CA2940226A1 (en) | 2013-02-22 | 2014-08-28 | The Regents Of The University Of California | Compositions and methods for promoting growth of beneficial microbes to treat or prevent disease or prolong life |
| KR20150134356A (ko) | 2013-03-05 | 2015-12-01 | 리엑스유니버시테이트 그로닝겐 | 염증을 억제하기 위한 페칼리 박테리움 프라우스니치이 htf-f (dsm 26943)의 용도 |
| RU2015140610A (ru) | 2013-03-14 | 2017-04-17 | ТЕРАБАЙОМ, ЭлЭлСи | Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств |
| HK1220495A1 (zh) * | 2013-03-14 | 2017-05-05 | Seres Therapeutics, Inc. | 从材料和组合物中检测和富集病原体的方法 |
| WO2014145970A1 (en) | 2013-03-15 | 2014-09-18 | President And Fellows Of Harvard College | Modulation of regulatory t cells via g-coupled protein receptor 43 |
| WO2014150094A1 (en) | 2013-03-15 | 2014-09-25 | University Of Florida Research Foundation, Inc. | Butyrogenic bacteria as probiotics to treat clostridium difficile |
| WO2014145958A2 (en) | 2013-03-15 | 2014-09-18 | Seres Health, Inc. | Network-based microbial compositions and methods |
| CN103142656A (zh) | 2013-03-18 | 2013-06-12 | 广州知光生物科技有限公司 | 脆弱拟杆菌在制备防治结肠癌组合物中的应用 |
| CN103156888A (zh) | 2013-03-18 | 2013-06-19 | 广州知光生物科技有限公司 | 脆弱拟杆菌在制备治疗炎症性肠病组合物中的应用 |
| CN103146620A (zh) | 2013-03-25 | 2013-06-12 | 广州知光生物科技有限公司 | 具有益生菌特性的脆弱拟杆菌 |
| JP2014196260A (ja) | 2013-03-29 | 2014-10-16 | 公立大学法人奈良県立医科大学 | 慢性閉塞性肺疾患の予防又は治療用組成物 |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| EP2994161B1 (en) | 2013-05-10 | 2020-10-28 | California Institute of Technology | Probiotic prevention and treatment of colon cancer |
| WO2014197562A1 (en) | 2013-06-05 | 2014-12-11 | Rebiotix, Inc. | Microbiota restoration therapy (mrt), compositions and methods of manufacture |
| US9511099B2 (en) | 2013-06-05 | 2016-12-06 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
| WO2014201037A2 (en) * | 2013-06-10 | 2014-12-18 | New York University | Methods for manipulating immune responses by altering microbiota |
| WO2014200334A1 (en) | 2013-06-14 | 2014-12-18 | N.V. Nutricia | Synbiotic composition for treatment of infections in allergic patients |
| WO2015003001A1 (en) | 2013-07-01 | 2015-01-08 | The Washington University | Methods for identifying supplements that increase gut colonization by an isolated bacterial species, and compositions derived therefrom |
| WO2015003305A1 (zh) | 2013-07-08 | 2015-01-15 | 吉瑞高新科技股份有限公司 | 电子烟盒 |
| US9764019B2 (en) | 2013-07-09 | 2017-09-19 | Vedanta Biosciences, Inc. | Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease |
| GB2535034A (en) | 2013-07-21 | 2016-08-10 | Whole Biome Inc | Methods and systems for microbiome characterization, monitoring and treatment |
| US20160192689A1 (en) | 2013-07-31 | 2016-07-07 | Wikifoods, Inc. | Encapsulated functional food compositions |
| WO2015021936A1 (en) | 2013-08-16 | 2015-02-19 | The University Of Hong Kong | Method and compositions for treating cancer using probiotics cross-reference to related application |
| CN103509741B (zh) | 2013-08-22 | 2015-02-18 | 河北农业大学 | 布劳特菌auh-jld56及其在牛蒡苷元转化中的应用 |
| WO2015038731A1 (en) | 2013-09-12 | 2015-03-19 | The Johns Hopkins University | Biofilm formation to define risk for colon cancer |
| EP3071052B1 (en) | 2013-10-18 | 2020-02-26 | InnovaChildfood AB | A nutritionally balanced composite meal for infants and small children and a method of producing said meal |
| PL229020B1 (pl) | 2013-11-13 | 2018-05-30 | Inst Biotechnologii Surowic I Szczepionek Biomed Spolka Akcyjna | Nowy szczep Bifidobacterium breve |
| EP3074027B1 (en) | 2013-11-25 | 2024-12-18 | Seres Therapeutics, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| EP3082431A4 (en) | 2013-12-16 | 2017-11-15 | Seres Therapeutics, Inc. | Bacterial compositions and methods of use thereof for treatment of immune system disorders |
| CN103981117B (zh) | 2013-12-24 | 2018-10-26 | 北京大伟嘉生物技术股份有限公司 | 一株高抗逆性屎肠球菌及其培养方法和应用 |
| CN103981115B (zh) | 2013-12-24 | 2018-10-26 | 北京大伟嘉生物技术股份有限公司 | 一株高抗逆性屎肠球菌及其应用 |
| CN103820363B (zh) | 2014-01-27 | 2016-02-24 | 福建省农业科学院生物技术研究所 | 一种屎肠球菌菌粉的制备与应用 |
| CN103865846B (zh) | 2014-02-27 | 2016-03-30 | 扬州绿保生物科技有限公司 | 一种屎肠球菌及其制备方法 |
| CN103849590B (zh) | 2014-03-25 | 2016-07-06 | 上海交通大学 | 一株耐酸短双歧杆菌BB8dpH及其应用 |
| KR101683474B1 (ko) | 2014-03-26 | 2016-12-08 | 주식회사 쎌바이오텍 | 과민성 대장 증후군 예방 또는 치료용 조성물 |
| US9783858B2 (en) | 2014-04-02 | 2017-10-10 | Northwestern University | Altered microbiome of chronic pelvic pain |
| KR101583546B1 (ko) | 2014-04-09 | 2016-01-11 | 국립암센터 | 유전자 다형성을 이용한 소라페닙 치료에 대한 반응성 예측방법 |
| MX387331B (es) * | 2014-04-10 | 2025-03-18 | Riken | Composiciones y metodos para induccion de celulas th17. |
| CN104195075B (zh) | 2014-08-14 | 2017-04-19 | 生合生物科技股份有限公司 | 一种屎肠球菌ef08及包含它的饲料添加物和饲料 |
| WO2015168534A1 (en) | 2014-05-02 | 2015-11-05 | Novogy, Inc. | Therapeutic treatment of gastrointestinal microbial imbalances through competitive microbe displacement |
| JP6629840B2 (ja) | 2014-05-08 | 2020-01-15 | パノプテス・ファーマ・ゲーエムベーハー | 眼の疾患および障害を処置するための化合物 |
| CN106687130B (zh) | 2014-08-05 | 2020-01-21 | 深圳华大基因科技有限公司 | 真杆菌属在预防和治疗结直肠癌相关疾病中的用途 |
| EP3188741A4 (en) | 2014-08-28 | 2018-03-28 | Yale University | Compositions and methods for the treating an inflammatory disease or disorder |
| US20160058808A1 (en) | 2014-09-03 | 2016-03-03 | California Institute Of Technology | Microbe-based modulation of serotonin biosynthesis |
| CN104546935A (zh) | 2014-09-30 | 2015-04-29 | 深圳华大基因科技有限公司 | 多形拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用 |
| CN104546940A (zh) | 2014-09-30 | 2015-04-29 | 深圳华大基因科技有限公司 | 平常拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用 |
| CN104546933A (zh) | 2014-09-30 | 2015-04-29 | 深圳华大基因科技有限公司 | 粪拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用 |
| CN104546934B (zh) | 2014-09-30 | 2019-04-09 | 深圳华大基因科技有限公司 | 粪副拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用 |
| CN104546942A (zh) | 2014-09-30 | 2015-04-29 | 深圳华大基因科技有限公司 | 多氏拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用 |
| CN104546932A (zh) | 2014-09-30 | 2015-04-29 | 深圳华大基因科技有限公司 | 卵形拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用 |
| US10046030B2 (en) | 2014-10-07 | 2018-08-14 | University Of Virginia Patent Foundation | Compositions and methods for preventing and treating infection |
| MX382478B (es) | 2014-10-24 | 2025-03-13 | Infinant Health Inc | Bifidobacterias activadas y metodos de uso de las mismas. |
| HK1244461A1 (zh) | 2014-10-30 | 2018-08-10 | 加利福尼亚技术学院 | 用於改善神经发育障碍中的行为的包含细菌的组合物和方法 |
| EP3212207A4 (en) | 2014-10-30 | 2018-06-13 | California Institute of Technology | Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders |
| SG10201903823QA (en) | 2014-10-31 | 2019-05-30 | Whole Biome Inc | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| CN104435000A (zh) | 2014-11-12 | 2015-03-25 | 江南大学 | 乳酸菌对支气管哮喘治疗中的应用 |
| MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| DK3223835T3 (en) | 2014-11-25 | 2025-02-17 | Memorial Sloan Kettering Cancer Center | Intestinal microbiota and gvhd |
| EP3193901B1 (en) | 2014-12-23 | 2018-04-04 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| ES2658310T3 (es) | 2014-12-23 | 2018-03-09 | 4D Pharma Research Limited | Una cepa de bacteroides thetaiotaomicron y su uso en la reducción de la inflamación |
| CN104560820B (zh) | 2014-12-30 | 2017-10-20 | 杭州师范大学 | 屎肠球菌kq2.6及应用 |
| KR102735818B1 (ko) | 2015-01-23 | 2024-11-28 | 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 암 예방에서 단쇄 지방산의 용도 |
| CN105982919A (zh) | 2015-02-26 | 2016-10-05 | 王汉成 | 生物减速剂抗癌技术 |
| WO2016139217A1 (en) | 2015-03-04 | 2016-09-09 | Ab-Biotics, S.A. | Composition comprising anaerobically cultivated human intestinal microbiota |
| SG11201707657UA (en) | 2015-03-18 | 2017-10-30 | Whole Biome Inc | Methods and compositions relating to microbial treatment and diagnosis of skin disorders |
| WO2016149449A1 (en) | 2015-03-18 | 2016-09-22 | Tufts University | Compositions and methods for preventing colorectal cancer |
| KR102661603B1 (ko) | 2015-06-01 | 2024-04-29 | 더 유니버서티 오브 시카고 | 공생 미생물총의 조작에 의한 암의 치료 |
| MA55434B1 (fr) | 2015-06-15 | 2022-02-28 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| PT3307288T (pt) | 2015-06-15 | 2019-10-17 | 4D Pharma Res Ltd | Composições compreendendo estirpes bacterianas |
| TWI759266B (zh) | 2015-06-15 | 2022-04-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物之用途 |
| CN108135945A (zh) | 2015-06-22 | 2018-06-08 | 哈佛大学校长及研究员协会 | 固有层调节性t细胞的诱导 |
| CN105112333A (zh) | 2015-08-31 | 2015-12-02 | 江南大学 | 一种具有良好肠道定殖能力的长双歧杆菌及筛选方法和应用 |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| MA45287A (fr) | 2015-11-20 | 2018-08-22 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| CA3006105A1 (en) | 2015-11-25 | 2017-06-01 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for reducing vancomycin-resistant enterococci infection or colonization |
| PT3313423T (pt) | 2016-03-04 | 2019-07-10 | 4D Pharma Plc | Composições que compreendem a estirpe blautia bacteriana para tratar a hipersensibilidade visceral |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| WO2018112365A2 (en) | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii |
| US20190314427A1 (en) | 2016-12-16 | 2019-10-17 | Evelo Biosciences, Inc. | Methods of treating cancer using parabacteroides |
| WO2018215782A1 (en) | 2017-05-24 | 2018-11-29 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
-
2016
- 2016-06-15 TW TW105118812A patent/TWI759266B/zh not_active IP Right Cessation
- 2016-06-15 SG SG10201912324XA patent/SG10201912324XA/en unknown
- 2016-06-15 CA CA2988661A patent/CA2988661A1/en not_active Abandoned
- 2016-06-15 SM SM20190588T patent/SMT201900588T1/it unknown
- 2016-06-15 MD MDE20170262T patent/MD3240554T2/ro not_active IP Right Cessation
- 2016-06-15 JP JP2017501394A patent/JP6426265B2/ja not_active Expired - Fee Related
- 2016-06-15 LT LT16731640T patent/LT3240554T/lt unknown
- 2016-06-15 ES ES16731640T patent/ES2753779T3/es active Active
- 2016-06-15 EP EP16731640.5A patent/EP3240554B1/en not_active Revoked
- 2016-06-15 EA EA201890048A patent/EA201890048A1/ru unknown
- 2016-06-15 HR HRP20191949TT patent/HRP20191949T1/hr unknown
- 2016-06-15 MX MX2017016560A patent/MX2017016560A/es unknown
- 2016-06-15 HU HUE16731640A patent/HUE045754T2/hu unknown
- 2016-06-15 SG SG10201912323VA patent/SG10201912323VA/en unknown
- 2016-06-15 AU AU2016278067A patent/AU2016278067B2/en active Active
- 2016-06-15 PE PE2017002701A patent/PE20180243A1/es unknown
- 2016-06-15 CN CN201680040548.6A patent/CN108271354B/zh active Active
- 2016-06-15 MA MA051639A patent/MA51639A/fr unknown
- 2016-06-15 WO PCT/GB2016/051770 patent/WO2016203218A1/en not_active Ceased
- 2016-06-15 TW TW111107417A patent/TW202223083A/zh unknown
- 2016-06-15 SI SI201630451T patent/SI3240554T1/sl unknown
- 2016-06-15 DK DK16731640T patent/DK3240554T3/da active
- 2016-06-15 PL PL16731640T patent/PL3240554T3/pl unknown
- 2016-06-15 KR KR1020187000112A patent/KR20180012846A/ko not_active Ceased
- 2016-06-15 BR BR112017025005-5A patent/BR112017025005A2/pt not_active Application Discontinuation
- 2016-06-15 RS RSP20191379 patent/RS59446B1/sr unknown
- 2016-06-15 CN CN202210517235.2A patent/CN115364122A/zh active Pending
- 2016-06-15 PT PT167316405T patent/PT3240554T/pt unknown
- 2016-06-15 EP EP19189140.7A patent/EP3636272A1/en not_active Withdrawn
-
2017
- 2017-08-09 US US15/673,270 patent/US10322151B2/en active Active
- 2017-11-16 ZA ZA2017/07772A patent/ZA201707772B/en unknown
- 2017-11-19 IL IL255757A patent/IL255757A/en unknown
- 2017-12-27 CO CONC2017/0013443A patent/CO2017013443A2/es unknown
-
2018
- 2018-10-24 JP JP2018200128A patent/JP2019048823A/ja active Pending
-
2019
- 2019-02-01 US US16/265,238 patent/US11389493B2/en active Active
- 2019-10-31 CY CY20191101133T patent/CY1122344T1/el unknown
-
2022
- 2022-04-05 JP JP2022063077A patent/JP2022088637A/ja active Pending
- 2022-06-07 US US17/833,962 patent/US20230173001A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2753779T3 (es) | Blautia stercosis y wexlerae para la utilización en el tratamiento de enfermedades inflamatorias y autoinmunes | |
| ES2758679T3 (es) | Composiciones que comprenden cepas bacterianas | |
| ES2748826T3 (es) | Composiciones que comprenden cepas bacterianas | |
| ES2748812T3 (es) | Composiciones que comprenden cepas bacterianas | |
| ES2914430T3 (es) | Composiciones que comprenden cepas bacterianas | |
| ES2818991T3 (es) | Composiciones que comprenden cepas bacterianas | |
| ES2766867T3 (es) | Composiciones que comprenden cepas bacterianas | |
| ES2705157T3 (es) | Composiciones que comprenden cepas bacterianas | |
| HK1260125B (en) | Compositions comprising bacterial strains | |
| HK1240835B (en) | Compositions comprising bacterial strains | |
| HK1240835A1 (en) | Compositions comprising bacterial strains | |
| HK40030608A (en) | Compositions comprising bacterial strains | |
| HK1244202B (en) | Blautia stercosis and wexlerae for use in treating inflammatory and autoimmune diseases | |
| HK1240831B (en) | Compositions comprising bacterial strains | |
| HK1240831A1 (en) | Compositions comprising bacterial strains | |
| HK1246675B (en) | Compositions comprising bacterial strains |